Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18730913 | SYSTEMS AND METHODS FOR SKIN BIOMOLECULAR PROFILE ASSESSMENT USING ARTIFICIAL INTELLIGENCE | July 2024 | February 2026 | Abandon | 19 | 1 | 0 | No | No |
| 18717457 | DISPLAYING RELEVANT PRIOR REPORTS IN A TELEMEDICINE SETTING | June 2024 | February 2026 | Abandon | 20 | 1 | 0 | No | No |
| 18656101 | SYSTEMS AND METHODS FOR DRUG-AGNOSTIC PATIENT-SPECIFIC DOSING REGIMENS | May 2024 | October 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18407756 | PROTOCOL COMPLIANCE SYSTEM | January 2024 | March 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18385530 | SYSTEMS, METHODS, AND APPARATUSES FOR SECURE DIAGNOSIS AND TREATMENTS AND AUTHENTICATING DIAGNOSED USERS | October 2023 | December 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18270748 | SYSTEM AND METHOD FOR MEASURING AN INDIVIDUAL'S HEALTH AND FITNESS LEVELS | July 2023 | August 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18332934 | MEDICAL SYSTEM WITH DOCKING STATION AND MOBILE MACHINE | June 2023 | March 2025 | Abandon | 21 | 2 | 0 | Yes | No |
| 18107050 | CLINICAL TRIAL VERIFICATION SYSTEM AND METHOD IMPROVEMENT INCLUDING A COMBINED SCREENSHARING, VIDEO CONFERENCING, SOURCE CAPTURE AND eCRF/CLINICAL TRIAL DOCUMENT RECONCILIATION SYSTEM | February 2023 | October 2025 | Abandon | 33 | 1 | 0 | No | No |
| 18018427 | METHOD AND SYSTEM FOR DETERMINING POPULATION PHARMACOKINETIC MODEL OF PROPOFOL AND DERIVATIVE THEREOF | January 2023 | January 2026 | Abandon | 35 | 2 | 0 | No | No |
| 18076452 | AUTOMATED TICKET ATTACHMENT CREATION | December 2022 | December 2025 | Abandon | 36 | 2 | 0 | No | No |
| 17978790 | Capturing Detailed Structure from Patient-Doctor Conversations for Use in Clinical Documentation | November 2022 | January 2026 | Abandon | 38 | 4 | 0 | Yes | No |
| 17922017 | DISEASE PREDICTION METHODS AND DEVICES, ELECTRONIC DEVICES, AND COMPUTER READABLE STORAGE MEDIA | October 2022 | November 2025 | Abandon | 37 | 2 | 0 | Yes | No |
| 17958756 | SYSTEM AND METHOD FOR CREDENTIALING HEALTHCARE PROVIDERS | October 2022 | March 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17929757 | INFORMATION PROCESSING APPARATUS, INFORMATION PROCESSING METHOD, AND INFORMATION PROCESSING PROGRAM | September 2022 | June 2025 | Abandon | 33 | 2 | 0 | No | No |
| 17801745 | BIOMARKER COMPUTING DEVICE AND BIOMARKER COMPUTING METHOD | August 2022 | January 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17819609 | SYSTEMS AND METHODS FOR DIGITAL IMAGING AND COMMUNICATIONS IN MEDICINE FILE PROCESSING | August 2022 | June 2025 | Abandon | 34 | 2 | 0 | No | No |
| 17863476 | SYSTEM AND METHOD FOR CARING FOR PATIENTS BY USING A SMART DIAPER | July 2022 | December 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17860086 | MANAGING SERVER, MANAGING METHOD AND COMPUTER PROGRAM FOR OPERATING BIOMETRIC INFORMATION-BASED ACCESS MANAGEMENT SYSTEM | July 2022 | June 2025 | Abandon | 36 | 2 | 0 | Yes | No |
| 17729535 | SYSTEMS FOR MANAGING ALARMS FROM MEDICAL DEVICES | April 2022 | November 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17568291 | PATIENT MANAGEMENT SYSTEM | January 2022 | May 2025 | Abandon | 40 | 2 | 0 | No | No |
| 17608374 | TRACKING AND VALIDATING TIME OF PORTABLE DIGITAL RECORDING DEVICES | November 2021 | May 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17452899 | OMNICHANNEL THERAPEUTIC PLATFORM | October 2021 | October 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17451465 | SYSTEM AND METHODS FOR EXAM SUGGESTIONS USING A DATABASE | October 2021 | October 2025 | Abandon | 48 | 3 | 0 | Yes | No |
| 17500909 | MEDICAL REMOTE DATA MONITORING AND FEEDBACK FOR IMPROVED OUTCOMES | October 2021 | December 2025 | Abandon | 50 | 3 | 0 | Yes | No |
| 17424329 | REHABILITATION SYSTEM AND IMAGE PROCESSING APPARATUS FOR HIGHER BRAIN DYSFUNCTION | July 2021 | December 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 17415048 | INTEGRATED DIAGNOSTICS SYSTEMS AND METHODS | June 2021 | December 2025 | Abandon | 54 | 4 | 0 | No | No |
| 17414937 | METHODS AND SYSTEMS FOR RADIOTHERAPY TREATMENT PLANNING BASED ON DEEP TRANSFER LEARNING | June 2021 | November 2025 | Allow | 53 | 4 | 0 | Yes | Yes |
| 17413432 | BONE DENSITY MODELING AND ORTHOPEDIC SURGICAL PLANNING SYSTEM | June 2021 | October 2025 | Abandon | 53 | 4 | 0 | Yes | No |
| 17299442 | Medical Data Management Method, Apparatus, System, and Server | June 2021 | February 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17335669 | EFFICIENCY OF MOTION MONITORING AND ANALYSIS FOR A SURGICAL PROCEDURE | June 2021 | January 2026 | Abandon | 55 | 5 | 0 | No | No |
| 17331623 | Method and System for Remote Augmented Reality Medical Examination | May 2021 | September 2025 | Abandon | 52 | 3 | 0 | No | No |
| 17243064 | SYSTEM AND METHOD FOR GRAPHICAL USER INTERFACE MANAGEMENT PROVIDING HISTORICAL DATA-BASED FORECASTING FOR CLINICAL TRIALS | April 2021 | October 2024 | Abandon | 42 | 4 | 0 | No | No |
| 17156278 | COOPERATIVE PROCESSING OF SURGICAL SENSOR-DATA STREAMS | January 2021 | September 2025 | Abandon | 56 | 6 | 0 | No | No |
| 17129336 | HEALTHCARE CONTENT MANAGEMENT SYSTEM | December 2020 | August 2025 | Abandon | 56 | 4 | 0 | Yes | No |
| 17125499 | DYNAMIC EPISODIC NETWORKS | December 2020 | October 2024 | Abandon | 46 | 1 | 0 | No | No |
| 17059950 | DIAGNOSIS SUPPORT SYSTEM | November 2020 | November 2024 | Abandon | 47 | 3 | 0 | No | No |
| 16938816 | DEVICE FOR MEASURING ENVIRONMENTAL FACTORS AND RECOMMENDING PERSONALIZED MITIGATING REGIMEN | July 2020 | February 2026 | Abandon | 60 | 7 | 0 | Yes | Yes |
| 16896694 | UI DESIGN FOR PATIENT AND CLINICIAN CONTROLLER DEVICES OPERATIVE IN A REMOTE CARE ARCHITECTURE | June 2020 | November 2025 | Allow | 60 | 7 | 1 | No | No |
| 16858407 | MULTI-MODALITY ELECTRONIC INVITE ROUTING SYSTEM AND PROCESS FOR TELEHEALTH LANGUAGE INTERPRETATION SESSION | April 2020 | November 2024 | Abandon | 54 | 2 | 0 | No | Yes |
| 16803800 | CONNECTIVITY INFRASTRUCTURE FOR A TELEHEALTH PLATFORM WITH THIRD-PARTY WEB SERVICES | February 2020 | March 2025 | Abandon | 60 | 4 | 0 | No | Yes |
| 16422934 | DIABETES RISK ENGINE AND METHODS THEREOF FOR PREDICTING DIABETES PROGRESSION AND MORTALITY | May 2019 | February 2025 | Abandon | 60 | 7 | 0 | Yes | No |
| 16373619 | System and method for using unique identifying data for precautionary determination to send notifications to a user to reduce potential negative health outcomes related to implantable devices and recall, adverse event data | April 2019 | November 2024 | Abandon | 60 | 2 | 0 | No | Yes |
| 16010215 | GEOGRAPHIC UTILIZATION OF ARTIFICIAL INTELLIGENCE IN REAL-TIME FOR DISEASE IDENTIFICATION AND ALERT NOTIFICATION | June 2018 | January 2025 | Abandon | 60 | 8 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KANAAN, LIZA TONY.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KANAAN, LIZA TONY works in Art Unit 3683 and has examined 23 patent applications in our dataset. With an allowance rate of 17.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 53 months.
Examiner KANAAN, LIZA TONY's allowance rate of 17.4% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KANAAN, LIZA TONY receive 3.83 office actions before reaching final disposition. This places the examiner in the 96% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by KANAAN, LIZA TONY is 53 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +26.2% benefit to allowance rate for applications examined by KANAAN, LIZA TONY. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 3.8% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 9.1% of cases where such amendments are filed. This entry rate is in the 9% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 99% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 25.0% of appeals filed. This is in the 3% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 133.3% are granted (fully or in part). This grant rate is in the 97% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 40% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 43% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.